Moderate to severe allergic rhinitis or rhinoconjunctivitis with or without controlled asthma due to natural sensitisation to grass pollen
Conditions
Interventions
Group 1: Data on the symptom level and intake of anti-allergic medication will be collected from around 600 patients during the 2025 grass pollen season.
Sponsors
Uniklinik Köln, Institut für Medizinische Statistik und Bioinformatik
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: -Dated and signed consent to the use of data, -Grass pollen allergy in at least 2 previous grass pollen seasons, -Intake of anti-allergic medication during 2 previous grass pollen seasons, -Positive skin prick test against grass pollen allergens (wheal =3 mm), positive control wheal = 3 mm, negative control (NaCl) wheal <2 mm.
Exclusion criteria
Exclusion criteria: -Participants who do not have access to a smartphone or tablet, -Positive skin prick test against house dust mite allergens (wheal =3 mm).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the CSMS as a mean over the month of June 2025. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are the daily symptom score (dSS) and the daily medication score (dMS), the symptoms of eyes, nose and general allergy symptoms recorded on VAS, and an asthma score. | — |
Countries
Germany
Contacts
Public ContactRalph Mösges
Uniklinik Köln, Institut für Medizinische Statistik und Bioinformatik
Outcome results
None listed